California official throws wrench in planned CVS-Aetna merger

The planned merger of CVS Health and Aetna hit a snag this week after California Insurance Commissioner Dave Jones urged the U.S. Department of Justice (DOJ) to block the $69 billion deal.

The news comes as investor Carl Icahn stated he would vote against the $54 billion purchase of Express Scripts Holdings by Cigna Corporation, The Wall Street Journal reported. The letter to DOJ is the first significant roadblock in CVS’s attempt to acquire Aetna. Last month, antitrust enforcers appeared less likely to move to block the deal, according to Bloomberg.

Jones took issue with the loss of Aetna as a competitor in the pharmacy benefit manager (PBM) market, announcing his findings and recommendations based on an in-depth review and analysis of the testimony, studies and written comments of a public hearing with expert testimony on the merger.

"A merger of this size and type, according to experts on health insurer and healthcare mergers, will likely lead to increased prices and decreased quality,” Jones said in a statement. “Further, partial divestiture or other remedies traditionally used by the Department of Justice will not adequately protect consumers or address the adverse consequences of a merger of CVS and Aetna. Traditional methods to avoid market concentration will not address potential impacts on service quality, the power to charge excessive rates, or the creation of barriers to block a potential market participant with the resources to enter into new markets.”

New entrants into the PBM space will also not be able to compete, he concluded. He requested that DOJ sue to block the transaction.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup